<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Optimind Pharma Corp. — News on 6ix</title>
    <link>https://6ix.com/company/optimind-pharma-corp</link>
    <description>Latest news and press releases for Optimind Pharma Corp. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 08 Sep 2025 19:18:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/optimind-pharma-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836831378dffbe2df16924e.webp</url>
      <title>Optimind Pharma Corp.</title>
      <link>https://6ix.com/company/optimind-pharma-corp</link>
    </image>
    <item>
      <title>Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk</title>
      <link>https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-announces-definitive-agreement-191800899</link>
      <guid isPermaLink="true">https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-announces-definitive-agreement-191800899</guid>
      <pubDate>Mon, 08 Sep 2025 19:18:00 GMT</pubDate>
      <description>Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the &quot;Optimind&quot; or the &quot;Company&quot;) is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the &quot;SEA&quot;) with IDesk Technologies Private Limited (&quot;InterviewDesk&quot;), a private company incorporated under laws of India, and its principal shareholders in respect of an arm&apos;s length transaction (the &quot;Transaction&quot;) which will change the business of the...</description>
    </item>
    <item>
      <title>Optimind Pharma Announces Termination of Letter of Intent</title>
      <link>https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-announces-termination-letter-200000572</link>
      <guid isPermaLink="true">https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-announces-termination-letter-200000572</guid>
      <pubDate>Thu, 04 Sep 2025 20:00:00 GMT</pubDate>
      <description>Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the &quot;Optimind&quot; or the &quot;Company&quot;) announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited (&quot;Monjin&quot;), with respect to the Company&apos;s acquisition of Monjin, has been mutually terminated by the parties.The Company is continuing to evaluate and review alternative acquisition opportunities.About the CompanyThe Company is a reporting issuer</description>
    </item>
    <item>
      <title>Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business</title>
      <link>https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-enters-letter-intent-034000974</link>
      <guid isPermaLink="true">https://6ix.com/company/optimind-pharma-corp/news/optimind-pharma-enters-letter-intent-034000974</guid>
      <pubDate>Tue, 25 Mar 2025 03:40:00 GMT</pubDate>
      <description>Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the &quot;Optimind&quot; or the &quot;Company&quot;) announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the &quot;LOI&quot;) to acquire all of the issued and outstanding shares (the &quot;Transaction&quot;) of Monjin Interviews Private Limited (&quot;Monjin&quot;), a corporation formed under the laws of India. The Transaction is an arm&apos;s length transaction.About Monjin - https://www.monjin.com/Redefining Recruitment wit</description>
    </item>
  </channel>
</rss>